A novel selective multi-targeted tyrosine kinase inhibitor with superior anti-tumor efficacy

被引：0
|
作者：
Hjarnaa, P. [1 ]
Fensholdt, Jef [1 ]
机构：
[1] LEO Pharma AS, Ballerup, Denmark
来源：
INFLAMMATION RESEARCH | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：S464 / S465
页数：2
相关论文
共 50 条
  • [21] Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo
    Li, Jing
    Li, Yan
    Feng, Zhi-qiang
    Chen, Xiao-guang
    CANCER LETTERS, 2009, 279 (02) : 213 - 220
  • [22] Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics
    Kozaki, Ryohei
    Yasuhiro, Tomoko
    Kato, Hikaru
    Murai, Jun
    Hotta, Shingo
    Ariza, Yuko
    Sakai, Shunsuke
    Fujikawa, Ryu
    Yoshida, Takao
    PLOS BIOLOGY, 2023, 21 (03)
  • [23] CHIR258, a novel multi-targeted tyrosine kinase inhibitor, for the treatment of t(4;14) multiple myeloma.
    Trudel, S
    Li, ZH
    Wei, E
    Wiesmann, M
    Rendahl, K
    Moler, E
    Chen, C
    Reece, D
    Mikhael, J
    Heise, C
    Stewart, AK
    BLOOD, 2004, 104 (11) : 185A - 185A
  • [24] Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics
    Kozaki, Ryohei
    Yasuhiro, Tomoko
    Kato, Hikaru
    Murai, Jun
    Hotta, Shingo
    Ariza, Yuko
    Sakai, Shunsuke
    Fujikawa, Ryu
    Yoshida, Takao
    PLOS ONE, 2023, 18 (03):
  • [25] Phase I study of SU014813, a novel oral multi-targeted receptor tyrosine kinase (RTK) inhibitor.
    Fiedler, W
    Giaccone, G
    Lasch, P
    Van der Horst, I
    Brega, NM
    Gentile, A
    Ljubimir, V
    Pithavala, YK
    Bokemeyer, C
    Boven, E
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9061S - 9061S
  • [26] Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
    Liang, Chris
    Yuan, Xiaobin
    Shen, Zhilin
    Wang, Yang
    Ding, Lieming
    MOLECULAR THERAPY-ONCOLYTICS, 2022, 24 : 577 - 584
  • [27] A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model
    Yanping Luo
    Fang Jiang
    Todd B. Cole
    Vincent P. Hradil
    David Reuter
    Arunava Chakravartty
    Daniel H. Albert
    Steven K. Davidsen
    Bryan F. Cox
    Evelyn M. McKeegan
    Gerard B. Fox
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 911 - 921
  • [28] Effects of a multi-targeted receptor tyrosine kinase inhibitor on radiosentization of head and neck squamous cell carcinoma
    Mirshahidi, Saied
    Hsu, Heng-Wei
    Chen, Chien-Shing
    JOURNAL OF IMMUNOLOGY, 2012, 188
  • [29] A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model
    Luo, Yanping
    Jiang, Fang
    Cole, Todd B.
    Hradil, Vincent P.
    Reuter, David
    Chakravartty, Arunava
    Albert, Daniel H.
    Davidsen, Steven K.
    Cox, Bryan F.
    McKeegan, Evelyn M.
    Fox, Gerard B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 911 - 921
  • [30] Evaluation of anti-osteoclastic activity of the novel, oral multi-targeted kinase inhibitor dasatinib (BMS-354825).
    Luo, FR
    Camuso, A
    McGlinchey, K
    Fager, K
    Flefleh, C
    Wen, ML
    Smykla, R
    Wescott, D
    Tamasi, J
    Feyen, J
    Hunt, J
    Kramer, R
    Lee, F
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9076S - 9077S
12345